The MFDS announced on the 13th that Moderna Korea has decided to allow manufacturing and sales items for Spikevax, which was applied on November 8.

Spikevax' is a COVID-19 vaccine produced by Samsung Biologics in Korea with vaccines such as Moderna Spikevax developed in Moderna, USA, which was approved for import on May 21.

Samsung Biologics receives raw material drugs and produces finished drugs through processes such as filling and marking. Spikevax is the first domestic consignment production vaccine in the mRNA method among COVID-19 vaccines licensed in Korea.

The MFDS said it expects the permit to contribute to the stable supply of COVID-19 vaccines in Korea as well as